Platelet Changes in Type 2 Diabetes

ConditionsPlatelet Indices Type 2 Diabetes Inflammatory Markers

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age30-70

SponsorAssiut University

About this trial

This study examines changes in platelet indices in people with type 2 diabetes compared to healthy people. It checks if these changes relate to inflammation markers (like hs-CRP) and blood sugar control. Participants get routine blood tests during one clinic visit at Assiut University Hospitals. No treatments or extra procedures are involved.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Adults aged 30-70 years.

Diagnosed T2DM for at least 1 year.

Fasting blood glucose ≥126 mg/dL and/or HbA1c ≥ 6.5%

Disqualifiers

Type 1 Diabetes Mellitus

Acute infection, chronic inflammatory disease

Malignancy.

Current use of anti-platelet or anti-inflammatory medications

Trial population

200 adults aged 30-70 years recruited from Assiut University Hospitals and clinics: 100 with type 2 diabetes mellitus (T2DM, diagnosed ≥1 year, fasting glucose ≥126 mg/dL or HbA1c ≥6.5%) and 100 healthy controls without diabetes or major illness. Both groups undergo single assessments of platelet indices (MPV, PDW, P-LCR, PCT via CBC), inflammatory markers (hs-CRP, ESR), and glycemic parameters (fasting/postprandial glucose, HbA1c).

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

Not listed

Trial groups

200 Participants

are grouped into 2 trial groups

Group A: T2DM Patients

Group B: Healthy Controls

Trial outcomes

Primary outcomes

Mean Platelet Volume (MPV)

Difference in mean platelet volume (MPV) measured from complete blood count between T2DM patients and healthy controls. MPV reflects platelet activation and size, expected to be elevated in T2DM due to inflammation and hyperglycemia.

Time frame

Single measurement at enrollment

Secondary outcomes

High-sensitivity C-reactive Protein (hs-CRP)

Serum levels of high-sensitivity C-reactive protein (hs-CRP) in T2DM patients compared to healthy controls, as a marker of systemic inflammation potentially linked to platelet changes.

Time frame

Single measurement at enrollment

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Assiut University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: